Cisplatin and Etoposide Concurrent with Radiotherapy in Non-Small Cell Lung Cancer: Single Institution Experience
/ 0
- Details
- Category: Vol. 81, June 2013
- Hits: 705
Cisplatin and Etoposide Concurrent with Radiotherapy in Non-Small Cell Lung Cancer: Single Institution Experience,HANY H. ELDEEB and SEHAM E. ABD-ELKHALK
Abstract
Introduction: Lung cancer is the most common cancer in the world and the leading cause of cancer-related deaths in Western countries. Phase III trials have demonstrated an improvement in survival with the combination of chemotherapy and radiotherapy over radiation alone for patients with a good performance status with stage III NSCLC.
Patients and Methods: This is a retrospective study of patients with unresectable NSCLC treated with radical chemo-radiotherapy at Northampton Oncology Centre in the period of May 2005-December 2010.
Results: There is a statistically significant advantage in overall survival for adenocarcinoma patients over those with squamous cell carcinoma p=0.033. Median overall survival (OS) for patients with adenocarcinoma was 37 months (std. error 13.098., 95% CI 11.328-62.672) while squamous cell carcinoma OS was 13 months (std error 7.115, 95% CI 000 26.946).
Conclusion: Our survival data for concurrent chemorad-iotherapy matches with the international published data. Future research is needed to define the best concurrent chemotherapy regimen as well as the role of consolidation and maintenance chemotherapy.